MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/diseases11030114

Медицинская библиотека · Diseases (Basel, Switzerland) · 2023

Case Report: Two Case Reports of Pulmonary Hypertension after mRNA COVID-19 Vaccination.

Sullivan Robert D, Shults Nataliia V, Suzuki Yuichiro J

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

We herein report two cases of sudden onset symptomatic pulmonary hypertension after coronavirus disease 2019 (COVID-19) vaccination.

CASE SUMMARY: Pulmonary hypertension in previously healthy adult males occurred within three weeks of receiving the second dose of the Pfizer (BNT162b2) mRNA COVID-19 vaccine from different lots. Both patients experienced a sudden onset of severe fatigue and dyspnea on exertion with negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) testing. The diagnosis was made by serial transthoracic echocardiography in the first case and by both transthoracic echocardiography and right heart catheterization in the second. Both cases resulted in functional limitations and likely permanent organ damage. No evidence of pulmonary emboli was detected in either case.

DISCUSSION: Pulmonary hypertension is a serious disease characterized by damage to lung vasculature and restricted blood flow through narrowed arteries from the right to left heart. The onset of symptoms is typically insidious, progressive and incurable, leading to right heart failure and premature death. The World Health Organization (WHO) classifies pulmonary hypertension into five categories and recently re-defined it as a resting mean pulmonary artery pressure greater than 20 mmHg. Sudden onset pulmonary hypertension would only be expected in the settings of surgical pneumonectomy or massive pulmonary emboli with compromise of at least 50% of the lung vasculature. We present here two novel cases of sudden onset pulmonary hypertension without evidence of pulmonary emboli, both of which occurred after receiving a COVID-19 mRNA vaccine.

Для цитирования: Sullivan Robert D, Shults Nataliia V, Suzuki Yuichiro J. Case Report: Two Case Reports of Pulmonary Hypertension after mRNA COVID-19 Vaccination.. Diseases (Basel, Switzerland). 2023. DOI: 10.3390/diseases11030114.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.